Protease Inhibitors (PIs)

PIs are another type of anti-HIV medication. The approval of the first PI by the FDA in 1995 led to the use of three-drug combinations (HAART), which had a large impact on the success of HIV treatment. By 1997, deaths associated with HIV infection were reduced by almost half.

How PIs work

PIs work by preventing HIV-infected cells from making new copies of the virus. PIs interfere with the assembly of new viruses.

FDA-approved PIs

For additional information about GlaxoSmithKline HIV products, please click on "Important Safety Information/
Indications."

Brand name Generic name Pharmaceutical company Prescribing Information for GlaxoSmithKline products Aptivus®* tipranavir Boehringer Ingelheim Crixivan®* indinavir sulfate Merck & Co. Invirase®* saquinavir mesylate Hoffmann-La Roche Kaletra®* lopinavir/ ritonavir Abbott Laboratories Lexiva® fosamprenavir calcium GlaxoSmithKline Prescribing Information Norvir®* ritonavir Abbott Laboratories Prezista™* darunavir Tibotec Reyataz®* atazanavir sulfate Bristol-Myers Squibb Viracept®* nelfinavir mesylate Pfizer

*The brands listed above are trademarks of their respective owners and are not trademarks of The GlaxoSmithKline Group of Companies. The makers of these brands are not affiliated with and do not endorse GlaxoSmithKline or its products.

This site is intended for US residents only.
© 1997-2008 GlaxoSmithKline. All Rights Reserved.
Legal Notices | Privacy Statement | Medicine Savings | Contact Us